In this latest returning episode of the Collaborative Business Podcast I’m in conversation with Michael W Young. We delve into the evolving landscape of partnerships within the pharmaceutical, biotech, and contract research sectors. An industry where collaboration is no longer a luxury but a necessity for innovation and survival.

Michael’s journey, spanning over 25 years in the industry, offers a unique perspective on why the traditional vertically integrated pharmaceutical model has given way to a networked, alliance-driven approach. The shift, he explains, is driven by the escalating costs and complexities of drug development, regulatory hurdles, and the imperative to accelerate time-to-market. In this environment, alliances have become the linchpin of success. These partnerships are not merely transactional but strategic, fostering shared goals, leveraged expertise, and mutual growth.

A standout theme in the discussion is the rise of service-based alliances, a concept Michael highlights as a growing yet under appreciated category. Unlike traditional procurement relationships, these alliances transform vendors into strategic partners, embedding them into the innovation pipeline. For instance, a contract research organisation (CRO) might collaborate with a diagnostic imaging provider not just for ad-hoc services but to co-develop solutions that enhance trial efficiency and data quality. The result? A win-win-win scenario: sponsors gain best-in-class capabilities, CROs expand their service offerings, and vendors deepen their market relevance.

Michael’s insights are grounded in real-world experience, including a pivotal alliance with an imaging company that redefined how data and commercial strategies could be integrated. His advice for organisations entering such partnerships is clear: clarity of expectations and measurable outcomes are non-negotiable. Alliances thrive when objectives are codified, shared, and revisited, ensuring alignment even as circumstances evolve. Metrics, he argues, should extend beyond financials to capture the intangibles: trust, communication, and the “feel” of the relationship. After all what lingers in memory years later isn’t the data points but the emotional resonance of the collaboration.

The conversation also touches on the broader implications of this shift. The days of corporate silos are fading; today’s life sciences ecosystem mirrors the interconnectedness of industries like automotive and high-tech, where innovation is a collective endeavour. Michael’s call to action was pragmatic in 2014 and still valid in 2026: invest in alliance management as a core competency. Whether through training, networking, or leveraging external expertise, organisations must recognise that collaboration is not a peripheral activity but a strategic imperative.

As the episode closes, Michael leaves us with a thought-provoking reminder: in a world where no company is an island, the ability to forge and sustain meaningful alliances may well be the defining skill of the 21st-century leader.

This episode is a must-listen for anyone curious about the future of collaboration in life sciences, or indeed, any industry where innovation hinges on the power of partnerships. Tune in, and discover how the art of alliance is reshaping business.

This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit petersimoons.substack.com